Announcements
- Enovis Announces First Quarter 2023 Results
- Enovis to Host First Quarter 2023 Results Conference Call on May 4th
- Enovis to Acquire Novastep
- ENOVIS™ Showcases Next Generation of Medical Technology at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting
- Newsweek Names Enovis™ as One of America’s Greatest Workplaces for Diversity 2023
- Enovis™ to Showcase Latest Innovations and Growing Foot & Ankle Portfolio at ACFAS 2023
- Enovis Expands Foot & Ankle Portfolio’s DynaClip® Family by Introducing Procedure-Specific Staples
- Enovis to Participate in the 41st Annual J.P. Morgan Healthcare Conference
- Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR® Ankle
- Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions
More ▼
Key statistics
As of last trade Enovis Corp (C520:FRA) traded at 49.20, 9.33% above its 52-week low of 45.00, set on Oct 11, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 49.20 |
---|---|
High | 49.20 |
Low | 49.20 |
Bid | 49.00 |
Offer | 49.20 |
Previous close | 49.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 54.50m |
Free float | 48.01m |
P/E (TTM) | -- |
Market cap | 2.89bn USD |
EPS (TTM) | -0.4469 USD |
Data delayed at least 15 minutes, as of May 31 2023 15:03 BST.
More ▼